CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Glenmark Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Glenmark Pharmaceuticals Ltd
B D S Marg
Chakala, Off Western Express Highway
Phone: +91 2240189999p:+91 2240189999 MUMBAI, 400099  India Ticker: GLENMARKGLENMARK
Business Summary
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Glenn M.Saldanha 54 1/1/2023 1/1/1998
Global Chief Financial Officer, Executive Director V. S.Mani 59 5/29/2018 11/16/2017
Compliance Officer, Company Secretary HarishKuber 3/31/2021 2/2/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Glenmark Generics Ltd B-2, Mahalaxmi Chambers MUMBAI India

Business Names
Business Name
532296
GLENMARK
Glenmark Pharmaceuticals
4 additional Business Names available in full report.

General Information
Number of Employees: 15,556 (As of 3/31/2023)
Outstanding Shares: 282,188,156 (As of 2/13/2024)
Shareholders: 285,461
Stock Exchange: NSE
Fax Number: +91 2240189986


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024